Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 24.0

Eligibility Criteria:
Inclusion Criteria:~* Participants of ASA class 1 - 3, above or equal to the age of 18 years;~* Participants scheduled for surgical procedures with an anticipated duration of anesthesia of at least 120 minutes, without further need for muscle relaxation other than for intubation;~* Participants scheduled for surgical procedures in supine position;~* Participants who had given written informed consent.~Exclusion Criteria:~* Participants in whom a difficult intubation because of anatomical malformations was expected;~* Participants known or suspected to have neuromuscular disorders impairing neuromuscular blocking and/or significant renal dysfunction;~* Participants known or suspected to have a (family) history of malignant hyperthermia;~* Participants known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;~* Participants receiving medication known to interfere with neuromuscular blocking agents, such as anticonvulsants and Mg\^2+;~* Participants who had already participated in this trial;~* Participants who had participated in another clinical trial, not pre-approved by the Sponsor, within 30 days of entering into this trial;~* Female participants who were pregnant: in females, pregnancy was to be excluded both from medical history and by a human chorionic gonadotropin (hCG) test within 24 hours before surgery except in females who were not of childbearing potential, i.e. at least 2 years menopausal or who had undergone tubal ligation or an hysterectomy;~* Female participants of childbearing potential not using any of the following methods of birth control (for one month): condom or diaphragm with spermicide, vasectomized partner (\>6 months), intrauterine device (IUD), abstinence;~* Female participants who were breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A. Placebo; 3 min after 1 mg/kg Esmeron® (Type: PLACEBO_COMPARATOR): Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm B. 2 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm C. 4 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm D. 8 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm E. 12 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm F. 16 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm G. Placebo; 15 min after 1 mg/kg Esmeron® (Type: PLACEBO_COMPARATOR): Placebo (single intravenous (IV) bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm H. 2 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm I. 4 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm J. 8 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm K. 12 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm L. 16 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
- Arm M. Placebo; 3 min after 1.2 mg/kg Esmeron® (Type: PLACEBO_COMPARATOR): Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm N. 2 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm O. 4 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm P. 8 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm Q. 12 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm R. 16 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm S. Placebo; 15 min after 1.2 mg/kg Esmeron® (Type: PLACEBO_COMPARATOR): Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm T. 2 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm U. 4 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm V. 8 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm W. 12 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
- Arm X. 16 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron® (Type: EXPERIMENTAL): Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete